CMO & CDMO Biotechnology Market Opportunities, Revenue Analysis, Market Growth, Trends, Service and Forecast 2022-2030:

A report on “CMO & CDMO Biotechnology Market” has been appended into the market research report database of Reports and Insights, in recent times, that promises to offer a complete analysis to its readers on the growth forecasts and development prospects of the market, together with the potential business opportunities in the industry. The study, which emphasizes the most recent  business dynamics, trends, growth drivers and opportunities that are impacting the market growth, also comprises the market size and the compounded average growth rate (CAGR) for the projected period 2022 and 2030. The report on “CMO & CDMO Biotechnology Market” also incorporates an in-depth assessment on both the macro- and micro-environmental factors that are likely to impact the market growth over the forecast period. In addition to that, analytical tools such as Porter’s five forces analysis and PESTEL analysis are utilized to reckon and gather the factors that are playing the role of the driving force for the growth of the market.

The global CMO & CDMO biotechnology market is expected to reach at a value of US$ 27.5 Bn by 2030 end at a CAGR of 10.8%

Request To Download Sample of CMO & CDMO Biotechnology Market Report:

Global CMO & CDMO Biotechnology Market, By CDMO Type (Whole Drug Development and Manufacturing, Active Pharmaceutical Ingredient (API) Manufacturing, Finished Dosage Formulation (FDF) Development and Manufacturing (Injectable)), By Therapeutic Area (Oncology, Infectious Diseases, Neurology, CVS, Metabolic Disorders/Endocrinology, Other Therapeutic Areas), By Product (Monoclonal Antibodies, Antibody Fragments, Recombinant Proteins, Vaccines, Biosimilars, Therapeutic Proteins, Others), By Molecule Type (Viral Vector Manufacturing, Cell and Gene Therapies (CGT), API manufacturing (Small molecule API manufacturers, Biologics API Manufacturing, Injectable manufacturing), By Application (Preclinical CMO/CDMO, Clinical CMO/CDMO, Commercial CMO/CDMO, Others), By Platform/ Expression System (Mammalian, Microbial (Bacteria, Yeast), Insect, Others), By End User (Pharmaceutical & Biotechnology Companies, Medical Device Companies, Academic Institutes and Research Centers) and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2022 and 2030.

The Contract Manufacturing Organization (CMO) and a Contract Development and Manufacturing Organization (CDMO) can be comprehended as the associations that provide development and manufacturing services to biotechnology/biopharmaceuticals companies on a contract basis to offer an extensive range of services, scaling from drug development through drug manufacturing.

Basically, pharma/biopharma and biotechnology companies’ associates with CDMOs as a means to outsource drug development and drug manufacturing. In the past few years, the contract research organization (CRO) and pharmaceutical contract development and manufacturing organization (CDMO) industries are witnessing a major breakthrough with regard to the significance and value of merger and acquisition (M&A) deals. Attributing to which, the global CMO & CDMO biotechnology market is projected to rise significantly over the years.

In addition to that, the higher use of pharmaceuticals, downsizing of supply chains to regional and national manufacturing centers, and emergence of novel advanced medicines urging robust investor interest in these business domains, are some other major factors that are projected to offer huge breakthroughs to the growth of the global CMO & CDMO biotechnology market in the forthcoming years.

Reports and Insights Study identifies some of the key participating players in the CMO & CDMO Biotechnology market globally are Boehringer Ingelheim Group, Wuxi Biologics, Samsung Biologics, Lonza Group, Fujifilm Diosynth Biotechnologies USA Inc., Toyobo Co. Limited, Parexel International Corporation, Icon PLC, Binex Co. Limited, JRS Pharma, Rentschler Biotechnologies, AGC Biologics, Sandoz Biopharmaceuticals (Novartis AG), Catalent Inc., AbbVie Contract Manufacturing, among others.

Factors that are benchmarked while estimating the market

Various factors that are benchmarked while estimating the market growth includes (but not restricted to):

New product designs and launches

Current product compliance


Concerns for use of CMO & CDMO Biotechnology

Advantages of CMO & CDMO Biotechnology

Actions taken by the manufacturer and respective regulatory authorities also impact the market growth of the segment. These factors are understood at regional level and in major countries globally for providing regional insights of the product segment in the report. This helps our clients to take informed decisions.

Contact Us

Reports and Insights

Tel: +1-(718)-312-8686

For Sales Query:

For New Topics & Other Info: